Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250512771363/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
01 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250501636359/en/Travere-Therapeutics-Reports-First-Quarter-2025-Financial-Results
24 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250424213901/en/Travere-Therapeutics-to-Report-First-Quarter-2025-Financial-Results
11 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250411452669/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
31 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250331803950/en/Travere-Therapeutics-to-Present-New-FILSPARI-sparsentan-Data-at-the-National-Kidney-Foundation-Spring-Clinical-Meetings-2025
17 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/17/3043582/0/en/Travere-Therapeutics-Submits-sNDA-to-FDA-for-Approval-of-FILSPARI-sparsentan-for-the-Treatment-of-FSGS.html
ABOUT THIS PAGE